drugset / Trial / NCT00320424

Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

NCT00320424

Phase 3 Completed 48 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study is requested by PMDA to confirm the efficacy and the safety for HFS.

Timeline

Start
2006-02-16
Primary completion
2006-10-26
Completion
2006-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Fondaparinux Other / unclassified